Additional file 1: of Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
- Narendra Bharathy (1944250)
- Noah Berlow (699844)
- Eric Wang (30587)
- Jinu Abraham (834945)
- Teagan Settelmeyer (6723350)
- Jody Hooper (4633564)
- Matthew Svalina (6723353)
- Zia Bajwa (4373284)
- Martin Goros (5832374)
- Brian Hernandez (6723356)
- Johannes Wolff (6723359)
- Ranadip Pal (590374)
- Angela Davies (6723362)
- Arya Ashok (6723365)
- Darnell Bushby (6723368)
- Maria Mancini (2600947)
- Christopher Noakes (6723371)
- Neal Goodwin (6723374)
- Peter Ordentlich (2703313)
- James Keck (783170)
- Douglas Hawkins (6723377)
- Erin Rudzinski (817852)
- Atiya Mansoor (4373287)
- Theodore Perkins (3582272)
- Christopher Vakoc (6723380)
- Joel Michalek (6723383)
- Charles Keller (234777)
Publication date
May 2019
DOIAbstract
Figure S1. Phosphohistone H3 (pHH3) expression and rhabdomyoblast count in VCR and ENT + VCR-treated eRMS. (a) pHH3 expression of eRMS mouse tumor (animal id: 67833) after treatment with single agent VCR. Scale Bar: 50 μM. (b) pHH3 expression of eRMS mouse tumor (animal id: 67822) after treatment with both ENT and VCR. Scale bar: 50 μM (c) Histological scoring of various mouse eRMS after four different types of treatment; DMSO, VCR, ENT, or a combination of ENT and VCR (ENT + VCR). Counted all fields 500 to 3000 cells under low and higher magnification on each slide. This count excluded endothelial cells and inflammatory cells. * denotes not determined while ** denotes myoglobin was immunohistochemically positive. (TIF 2381 kb
Add to ORKG